Sign In
Buy NUVL
$90.18
-1.17 (-1.28%)
At Close: Jun 03, 2026
Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session New Preclinical Data to be Presented on Parallel-lead, Clini
Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference
06:30am, Wednesday, 03'rd Aug 2022
CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas
Preclinical activity of ALK-selective inhibitor NVL-655 in a lorlatinib-resistant model of NSCLC with a compound resistance mutation continues to support potential for best-in-class profile CAMBRIDGE,
Nuvalent to Present at the 2022 Jefferies Healthcare Conference
06:38am, Thursday, 02'nd Jun 2022
CAMBRIDGE, Mass. , June 2, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference
06:30am, Thursday, 07'th Apr 2022
CAMBRIDGE, Mass. , April 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ: NUVL), a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL) a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today anno
Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference
06:30am, Tuesday, 04'th Jan 2022
CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in canc
New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC
09:21am, Thursday, 07'th Oct 2021
CAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in ca
Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
06:30am, Wednesday, 08'th Sep 2021
CAMBRIDGE, Mass., Sept. 8, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in ca
Nuvalent Announces Closing of Upsized Initial Public Offering
05:39pm, Monday, 02'nd Aug 2021
CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announ
5 Companies Join Robinhood in Going Public
03:11pm, Thursday, 29'th Jul 2021
Making their market debuts were three biotechs, a fintech, and a grill maker. Shares of one biotech, Icosavax, rocketed 214%.
Nuvalent Finalizes $151 Million IPO Plan
04:40am, Thursday, 29'th Jul 2021
Nuvalent Finalizes $151 Million IPO Plan
